Results 41 to 50 of about 9,997 (164)

A Perspective of Soy Isoflavones on Analytical, Biological, and Chemical Attributes

Legume Science, Volume 8, Issue 3, September 2026.
ABSTRACT This review covers key aspects of soybean (Glycine max), with a particular focus on its isoflavone content and biological properties. Soybeans maintain their position as both a nutraceutical and a pharmaceutical crop, with a broad range of dietary items used worldwide, including soy milk, fermented soy products, and various dietary supplements.
Sristy Suman, Joydeep Chatterjee, Gaurav Joshi, Raj Kumar, Muhammad Wahajuddin   +4 more
wiley   +1 more source

Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan

Kaohsiung Journal of Medical Sciences, 2017
Rivastigmine has been widely used in mild-to-moderate Alzheimer's disease (AD), but the therapeutic response rate varies from 20 to 60%. A dose-dependent effect has been suggested, but the plasma concentration of rivastigmine and its metabolite, NAP 226 ...
Tzu-Hua Chen, Mei-Chuan Chou, Chiou-Lian Lai, Shyh-Jong Wu, Chia-Ling Hsu, Yuan-Han Yang   +5 more
doaj   +1 more source

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil

Neuropsychiatric Disease and Treatment, 2012
Takemi Kimura, Junichi TakamatsuDivision of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto, JapanAbstract: Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years,
Kimura T, Takamatsu J
doaj  

Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
We present a set of multifunctional tacrine derivatives, designed with the CADMA‐Chem protocol, aimed for Alzheimer and Parkinson diseases. Of the tacrines designed, TAC‐674 and TAC‐678 are the best candidates to act as multifunctional antioxidants and neuroprotectors for Alzheimer and Parkinson diseases, respectively.
Eugenia Dzib, Luis Felipe Hernández‐Ayala, Silvana Silva‐Aguirre, Annia Galano   +3 more
wiley   +1 more source

Exploration of the Substrate Diversity of the Amine Transaminase 3FCR‐4M and its Engineered Variants

ChemCatChem, Volume 18, Issue 15, 14 August 2026.
We evaluated combinatorial variants of the engineered amine transaminase 3FCR‐4M in both kinetic resolution and asymmetric synthesis. This dual assessment revealed a striking discrepancy between high kinetic resolution activity and low asymmetric synthesis conversion, reflecting the inherent kinetic favorability of the deamination half‐reaction and ...
Konstantin F. G. Weigmann, Nils Michels, Mark Doerr, Uwe T. Bornscheuer   +3 more
wiley   +1 more source

Accelerated Biological Aging, Neurodegenerative Disease, and Mortality in Cardiovascular Disease Patients: Mediation and Modification Analysis

CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.
In cardiovascular disease (CVD) patients, accelerated biological aging is independently associated with elevated mortality risk, which is mediated by neurodegenerative disease. Early‐onset CVD amplifies the mortality risk, whereas a healthy lifestyle confers partial protection.
Jinyue Li, Han Ma, Guohua Wang
wiley   +1 more source

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents

Drug Development Research, Volume 87, Issue 5, August 2026.
ABSTRACT A series of novel chiral urea and thiourea compounds were designed as multitarget‐directed ligands for Alzheimer's disease and evaluated against hAChE, hBChE, and hMAO‐B, with exploratory assessment of HSD10. These chiral compounds were synthesized and fully characterized, and their enantiopurity was confirmed via HPLC.
Sule Erol Gunal, Senel Teke Tuncel, İlke Demir, İpek Baysal, Gökçen Telli, Safiye Sag Erdem, Gulberk Ucar, Michaela Hanzlova, Kamil Musilek, İlknur Dogan, Nesrin Gokhan Kelekci   +10 more
wiley   +1 more source

Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods

Heliyon
Alzheimer's disease is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles. Effective therapeutic strategies involve inhibiting the formation of beta-amyloid aggregates and destabilizing existing ones.
Fateme Davoudi, Nasrin Shadjou, Mahdieh Darroudi   +2 more
doaj   +1 more source

Discovery of a Potent and Selective MAO‐B Inhibitor From a Donepezil‐Linked Chalcone Library With Promising Antiparkinsonian Activity

Drug Development Research, Volume 87, Issue 5, August 2026.
ABSTRACT A focused library of 19 donepezil‐linked chalcones (DLCs) was efficiently synthesised through microwave‐assisted Claisen‐Schmidt condensation and subsequently profiled for their inhibitory activities against cholinesterases (AChE and BuChE) as well as monoamine oxidases (MAO‐A and MAO‐B).
Azize Kirac‐Aydin, Bishnu Prasad Pandey, Satyajit Mohanty, Rupsa Mondal, Abanish Biswas, Ashok Kumar Pattnaik, Subodh Mondal, Vinay N. Basavanakatti, Nilüfer Bayrak, Venkatesan Jayaprakash, Hoon Kim, Amaç Fatih TuYuN   +11 more
wiley   +1 more source